Two Sigma Advisers LP Raises Holdings in Medpace Holdings Inc (NASDAQ:MEDP)

Two Sigma Advisers LP raised its position in shares of Medpace Holdings Inc (NASDAQ:MEDP) by 12.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 428,700 shares of the company’s stock after acquiring an additional 48,800 shares during the period. Two Sigma Advisers LP owned approximately 1.20% of Medpace worth $22,691,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of MEDP. LS Investment Advisors LLC purchased a new stake in Medpace in the fourth quarter worth about $46,000. State of Alaska Department of Revenue purchased a new stake in shares of Medpace during the fourth quarter valued at about $92,000. NumerixS Investment Technologies Inc purchased a new stake in shares of Medpace during the fourth quarter valued at about $119,000. We Are One Seven LLC purchased a new stake in shares of Medpace during the fourth quarter valued at about $130,000. Finally, Great West Life Assurance Co. Can lifted its position in shares of Medpace by 270.1% during the third quarter. Great West Life Assurance Co. Can now owns 3,331 shares of the company’s stock valued at $200,000 after buying an additional 2,431 shares during the last quarter. Institutional investors and hedge funds own 83.17% of the company’s stock.

In other news, CEO August J. Troendle sold 600 shares of the firm’s stock in a transaction that occurred on Tuesday, January 15th. The shares were sold at an average price of $61.00, for a total transaction of $36,600.00. Following the sale, the chief executive officer now owns 603,702 shares of the company’s stock, valued at approximately $36,825,822. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 8,760 shares of the firm’s stock in a transaction that occurred on Thursday, January 17th. The stock was sold at an average price of $61.17, for a total transaction of $535,849.20. Following the sale, the chief executive officer now directly owns 603,702 shares in the company, valued at approximately $36,928,451.34. The disclosure for this sale can be found here. In the last quarter, insiders sold 705,800 shares of company stock worth $44,657,456. 29.50% of the stock is owned by corporate insiders.

Several research firms have commented on MEDP. BidaskClub lowered shares of Medpace from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 8th. TheStreet raised shares of Medpace from a “c” rating to a “b-” rating in a research report on Wednesday, April 10th. ValuEngine raised shares of Medpace from a “hold” rating to a “buy” rating in a research report on Thursday, January 10th. Wolfe Research started coverage on shares of Medpace in a report on Tuesday, April 2nd. They set an “outperform” rating on the stock. Finally, Zacks Investment Research downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $51.50.

Shares of MEDP traded up $0.12 during mid-day trading on Monday, hitting $58.88. 266,800 shares of the company traded hands, compared to its average volume of 673,758. Medpace Holdings Inc has a 1-year low of $35.00 and a 1-year high of $71.66. The company has a quick ratio of 0.69, a current ratio of 0.69 and a debt-to-equity ratio of 0.18. The company has a market cap of $2.11 billion, a P/E ratio of 22.73, a price-to-earnings-growth ratio of 1.91 and a beta of 1.62.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 25th. The company reported $0.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.07. Medpace had a net margin of 11.27% and a return on equity of 17.66%. The company had revenue of $192.12 million for the quarter, compared to the consensus estimate of $184.66 million. During the same quarter in the prior year, the company earned $0.39 EPS. Medpace’s quarterly revenue was up 70.5% on a year-over-year basis. On average, research analysts anticipate that Medpace Holdings Inc will post 2.64 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/15/two-sigma-advisers-lp-boosts-position-in-medpace-holdings-inc-medp.html.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Further Reading: Cash Flow Analysis in Stock Selection

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.